ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
7 announcements with these filters
Shilpa Medicare appointed Dr. Uday N. Harle as CEO of its wholly owned subsidiary, Shilpa Biologicals Private Limited. The appointment is effective from August 3, 2026.
Dr. Sridevi Khambhampaty resigned as CEO of Shilpa Biologicals Private Limited, effective 15 July 2026. The resignation from the material subsidiary is due to personal commitments.
Shilpa Medicare appointed Aneja Associates as Internal Auditor for a twelve-month term. The firm brings forty years of governance and risk experience to the company.
Shilpa Medicare Limited has appointed Dr. Vellaian Karuppiah as Chief Operating Officer (COO) effective April 23, 2026. Dr. Karuppiah brings over 33 years of pharmaceutical experience from firms like Gland Pharma and Dr. Reddy’s. He is expected to strengthen formulation business operations and enhance operational efficiencies.
Shilpa Medicare Limited has appointed Dr. Vellaian Karuppiah as Chief Operating Officer (COO) – Formulations, effective 23 April 2026. Dr. Karuppiah brings over 33 years of pharmaceutical experience from firms like Gland Pharma and Dr. Reddy’s. He is expected to strengthen the company’s formulation business and operational efficiencies.
Mr. Jayant Karajgi, the Chief Operating Officer (COO) - Formulations of Shilpa Medicare Limited, retired from his position effective April 22, 2026. He was categorized as Senior Management Personnel.
Dr. Jayant Karajgi, Chief Operating Officer (COO) – Formulations of Shilpa Medicare Limited, retired from the company effective April 22, 2026. He also ceased to be a Senior Management Personnel (SMP) on the same date. This leadership transition follows regulatory disclosure requirements under SEBI (LODR) Regulations, 2015.